Milestone Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for episodic cardiovascular conditions. The company's lead product, etripamil, is a calcium channel blocker formulated as a rapid-onset nasal spray designed for patient self-administration. Etripamil is FDA-approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to normal heart rhythm in adults. Beyond PSVT, Milestone is conducting clinical investigations into etripamil's potential for treating atrial fibrillation with rapid ventricular rate (AFib-RVR). The company operates with a lean organizational structure, emphasizing efficient spending on research and development rather than overhead costs. Milestone's leadership team comprises experienced pharmaceutical executives with expertise in cardiovascular medicine, clinical drug development, regulatory affairs, and commercialization. Headquartered in Montreal, Canada, the company was founded in 2003 and remains dedicated to addressing unmet needs in the treatment of acute and episodic cardiovascular conditions.